Caladrius and Cend Merge to Become Lisata Therapeutics

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)

Published: 30 Apr-2022

DOI: 10.3833/pdr.v2022.i4.2687     ISSN: 1756-7874

Section: Mergers & Acquisitions



Caladrius Biosciences and Cend Therapeutics have entered into a definitive merger agreement to form a combined company to be renamed Lisata Therapeutics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details